Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial

Abstract Background Respiratory syncytial virus (RSV) presents a global health concern. A lipid nanoparticle–encapsulated mRNA-based RSV vaccine (mRNA-1345) that encodes the membrane-anchored RSV prefusion–stabilized F glycoprotein is under clinical investigation. Methods This phase 1 dose escalatio...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of infectious diseases Vol. 230; no. 3; pp. e637 - e646
Main Authors:	Shaw, Christine A, Mithani, Runa, Kapoor, Archana, Dhar, Rakesh, Wilson, Lauren, El Asmar, Laila, Schnyder-Ghamloush, Sabine, Schaefers, Kristi, August, Allison, Stoszek, Sonia K, Chen, Grace L
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 23.09.2024
Subjects:	Adolescent Adult Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Female Healthy Volunteers Humans Immunogenicity, Vaccine Male Middle Aged mRNA Vaccines Nanoparticles - administration & dosage Respiratory Syncytial Virus Infections - immunology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Vaccines - administration & dosage Respiratory Syncytial Virus Vaccines - adverse effects Respiratory Syncytial Virus Vaccines - genetics Respiratory Syncytial Virus Vaccines - immunology Respiratory Syncytial Virus, Human - genetics Respiratory Syncytial Virus, Human - immunology RNA, Messenger - genetics RNA, Messenger - immunology Young Adult safety and immunogenicity mRNA-1345 respiratory syncytial virus mRNA vaccine younger adult
ISSN:	0022-1899, 1537-6613, 1537-6613
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!